evalu
frequenc
ari
il
jia
patient
impact
diseas
activ
assess
immunogen
safeti
effect
flu
vaccin
jia
patient
use
immunosuppress
drug
includ
surveil
flu
respiratori
viru
respiratori
syncyti
viru
rsv
metapneumoviru
mpv
parainfluenza
viru
piv
bocaviru
bov
adenoviru
adv
rhinoviru
rv
coronaviru
cov
conduct
jia
patient
attend
tertiari
pediatr
rheumatolog
clinic
march
august
jia
patient
includ
march
august
jia
patient
patient
present
sign
ari
andor
il
airway
secret
collect
period
combin
nasal
pharyng
swab
virus
detect
perform
use
real
time
pcr
qpcr
jia
patient
age
year
receiv
trival
split
flu
vaccin
asolomon
sanofi
pasteur
sa
butantan
institut
thirtyon
patient
mtx
leflunomid
antitnf
drug
time
vaccin
clinic
laboratori
evalu
includ
perform
surveil
period
vaccin
flu
titer
determin
hemagglutin
inhibit
hi
assay
day
vaccin
immun
respons
defin
seroconvers
greater
rise
hi
antibodi
seroprotect
hi
titer
least
surveil
period
ari
episod
report
patient
episod
il
sampl
collect
posit
least
one
respiratori
viru
flu
flu
b
rv
adv
piv
rsv
bov
hcov
viru
coinfect
detect
posit
sampl
period
jia
flare
observ
tempor
relationship
ari
without
plausibl
caus
may
trigger
event
seroprotect
rate
vaccin
higher
flu
strain
seroconvers
rate
exceed
gener
respons
flu
vaccin
influenc
therapeut
regimen
diseas
activ
patient
use
drug
present
lower
respons
strain
signific
differ
found
jia
activ
index
vaccin
patient
report
il
symptom
postvaccin
period
ari
rel
frequent
jia
patient
possibl
role
jia
flare
trival
split
flu
vaccin
seem
immunogen
safe
effect
jia
patient
use
immunosuppress
agent
given
children
jia
luciana
carvalho
none
e
paula
none
rodrigo
vd
silvestr
none
luciana
r
roberti
none
wyller
mello
none
eurico
arruda
none
virginia
pl
ferriani
none
